

**Amendment No. 3 to SB0529**

**Ford  
Signature of Sponsor**

**AMEND Senate Bill No. 529\***

**House Bill No. 702**

**FILED**

Date \_\_\_\_\_

Time \_\_\_\_\_

Clerk \_\_\_\_\_

Comm. Amdt. \_\_\_\_\_

by deleting subdivision (1) from the amendatory language of subsection (c) of Section 1 as amended and by substituting instead the following language:

(1) A presentation shall be limited to an agenda item and there shall be a maximum of three (3) presentations per agenda item;

AND FURTHER AMEND, by deleting subdivision (3) from the amendatory language of subsection (c) of Section 1 as amended and by substituting instead the following language:

(3) The time limit for a verbal presentation by or on behalf of a pharmaceutical manufacturer shall not exceed five (5) minutes in aggregate per drug per manufacturer or organization, or five (5) minutes by an individual, manufacturer or organization speaking on a particular position. The committee may, by a unanimous vote, extend the time limitation for presentation; and